Join the #FierceMadness!
Pick your favorite drug names in this year's tournament challenge. Read more and vote here!
Astellas has joined the biopharma who's who of companies to disclose federal scrutiny for donations to charities that help patients cover drug costs.
Eli Lilly faces allegations it ran a "multi-tiered kickback scheme" to pump up sales of key diabetes drugs.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
In the ongoing saga of Outcome Health, a judge yesterday denied a request by investors to freeze part of its funding.
Novartis is blazing ahead with its bid to take its CAR-T therapy Kymriah into new realms with a double-pronged application in Europe.
AstraZeneca is hoping a new formulation of Bydureon will give the med some competitive firepower against a field of tough rivals.
With an FDA committee nod, Novo Nordisk is one step closer to rolling out its key diabetes drug semaglutide—and launch preps are underway.
Samsung Bioepis has taken a big step toward approval for a Herceptin biosim in Europe.
Armed with a new cardiovascular benefit nod, Novo Nordisk’s diabetes fighter Victoza has a better shot at fighting off newer rivals.
Novartis’ Kisqali is playing from behind. But it just may have a shot at being No. 1 when it comes to snagging reimbursement in England.
Sorry, Tesaro. AZ's Lynparza won a broader-than-expected approval in ovarian cancer, putting it on even footing with Tesaro’s recent launch, Zejula.…